Skip to content

Self-Retaining Retractor in Obese Patients Undergoing Cesarean Section

The Effect of a Barrier Self-Retaining Retractor in Obese Patients Undergoing Cesarean Section

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01826604
Acronym
Alexis
Enrollment
301
Registered
2013-04-08
Start date
2013-01-31
Completion date
2014-09-30
Last updated
2016-10-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Obese, Pregnancy

Keywords

cesarean section, Pregnant

Brief summary

The purpose of this study is to investigate the effects of the Alexis O C-section retractor in obese patients (BMI ≥30 kg/m2) who undergo Cesarean sections. Patients will be randomized to the use of the Alexis retractor during Cesarean section (treatment group) or the use of traditional hand-held retractors (control group). We will determine if there is any difference in surgical site infection or wound disruption rates. We will also determine if there is a difference in the duration of surgery or length of time from skin incision to delivery of the infant, change in hemoglobin, estimated blood loss, and postoperative length of stay, intra-operative or postoperative anti-emetic requirements, need for hospital readmission or emergency room visits, or other complication rate between the two groups.

Detailed description

This study will be a prospective randomized-controlled trial. It will take place at a single site at St. Mary's Health Center in Richmond Heights, Missouri. Pregnant women with a BMI ≥ 30 kg/m2 who will be undergoing non-emergent Cesarean sections for delivery will be eligible. Exclusion criteria will be patients who are undergoing emergency Cesarean section, patients who are in an immunosuppressed state (ie, HIV, cancer), if they have a pre-existing infection other than chorioamnionitis at the time of the Cesarean section, or have received steroids for more than two days. Chorioamnionitis will be defined by the presence of fever, uterine fundal tenderness, maternal tachycardia (\>100 beats per minute), fetal tachycardia (\>160 beats per minute), or purulent or foul-smelling vaginal discharge or amniotic fluid \[15\]. All Cesarean sections will be performed for standard indications and not for the purpose of the study. After informed consent is obtained in patients who choose to participate, patients will be randomly assigned to either the control group (conventional hand-held retractors used only) or to the treatment group (Alexis O C-section self-retaining retractor used as well as any hand held retractors that are deemed necessary by the surgeon). Both types of retractors are commonly used for cesarean sections in obese patients and the choice of retractor is made by physician preference. There will be no other differences between the two groups. Randomization will occur using a computer-generated randomization process prior to the start of the study and the individual assignments will be placed in opaque sealed envelopes. After a patient agrees to participate in the study, an envelope will be selected and opened to assign the patient to either the treatment or control group. The Cesarean section will be performed for standard indications using standard surgical practice. All patients will receive pre-operative antibiotics according to St. Mary's Health Center standard practice. If the subcutaneous fat layer is \>2 cm, it will be closed with a suture layer as is accepted standard practice. Both of these measures have been showed to be associated with decreased risk of postoperative surgical site infection and are standard practice \[4, 16\]. The depth of the subcutaneous fat layer will be measured during the surgery using the sterile ruler that is provided as part of the standard Cesarean section surgical instrument tray set. If the patient is assigned to the Alexis retractor group, the Alexis retractor will be placed once the peritoneal incision has been made and extended adequately. The peritoneal incision is part of the usual surgical technique during Cesarean sections. The Alexis retractor will then be placed with the outer ring positioned external to the incision overlying the skin, the internal ring positioned inside the peritoneum against the anterior abdominal wall, with the connecting clear plastic barrier retracting the abdominal wall. The abdominal cavity will be palpated to ensure no abdominal organs have been inadvertently incorporated into the retractor as is the accepted protocol when using the Alexis retractor. All other aspects of the Cesarean section will be done routinely. Patients will be blinded to whether they were in the control or the treatment group. Postoperative care will be the same for both groups, according to standard practice. Patients will be followed until 30 days postpartum. They will be instructed to follow up for a postoperative incision check 1-2 weeks postoperatively. Patients will be contacted by telephone 30 days postoperatively to inquire if they have developed any type of surgical site infection in the 30 days postoperatively. They will be informed of this process during the consent process. Surgical site infections will be defined using the CDC criteria \[17\]. Information will be collected from the patient's hospital and clinic chart, including patient demographic information (patient BMI, maternal age, race, gestational age at delivery, number of previous surgeries, gravidity, parity, and maternal comorbidities); neonatal outcomes (infant weight, APGAR scores, need for NICU admission); indication for cesarean section; if the patient was laboring; the presence or absence of ruptured membranes (and length of time if ruptured membranes present); positive or negative GBS culture; the presence of chorioamnionitis; type of skin and uterine surgery; total duration of surgery and duration from skin incision until delivery of the infant; occurrance and type of infection; number of days postoperatively an infection occurred; depth of subcutaneous fat layer, estimated blood loss during surgery; change in hemoglobin from admission to postoperative Day #1 (a lab for hemoglobin and hematocrit drawn on postoperative Day #1 after a Cesarean section is part of routine care); requirement of intra-operative and postoperative anti-emetics; type of skin closure performed; length of postoperative hospital stay; presence of postoperative infection or wound disruption during hospital admission; the need for postoperative antibiotics; and other postoperative complications. Information will also be collected from the one to two week postoperative check, including presence of infection or wound disruption, need for postoperative antibiotics, need for wound opening or exploration, visits to the Emergency Room or need for hospital readmission. Information will be collected during the postoperative telephone call that occurs 30 days after the procedure. Participants will be asked the same questions which is on the attached question sheet, and includes whether the patient experienced a diagnosis of a postoperative infection, need for postoperative antibiotics, visit to the Emergency Room or hospital readmission, or other complication within 30 days after the Cesarean section.

Interventions

DEVICEAlexis O C-Section Retractor

The Alexis O C-section retractor will be used.

OTHERControl- Conventional retractors

Conventional hand-held retractors will be used. A self-retaining barrier retractor will not be used.

Sponsors

St. Louis University
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
FEMALE
Age
14 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

* Pregnant women * BMI greater than or equal to 30 kg/m squared * Aged 14-50 years old * Undergoing non-emergent cesarean section for delivery

Exclusion criteria

* Subjects undergoing emergency Cesarean-section * Pre-existing concurrent infection other than chorioamnionitis * State of immunosuppression (ie. HIV, cancer) * Long-term steroid use (\>2 days) * Subjects with a BMI \<30 kg/m2

Design outcomes

Primary

MeasureTime frameDescription
Wound Infection or DisruptionTime of surgery to 30 days post opWe will compare the number of patients with wound infections or disruptions when the Alexis O C-Section retractor is used vs when it is not used.

Secondary

MeasureTime frameDescription
Secondary Outcomes Will Include the Differences Between the Two Groups.From the time of surgery to 30 days post-op.Secondary outcomes will include the duration of surgery or length of time from skin incision to delivery of the infant, change in hemoglobin, estimated blood loss, and postoperative length of stay, intra-operative or postoperative anti-emetic requirements, need for hospital readmission or emergency room visits, or other complication rates between the two groups.

Countries

United States

Participant flow

Recruitment details

This was a randomized controlled trial of obese women (BMI ≥30 kg/m2) undergoing non-emergent Cesarean section at St. Mary's Health Center, March 2013 to September 2014. Patients were randomized to the treatment group (using the Alexis O C-section retractor) or to the control group (using conventional hand-held retractors).

Pre-assignment details

Non-emergent Cesarean delivery was defined by our institution's Cesarean section acuity scale, included those in which there was no immediate threat to the life of the patient or fetus. Not all Cesarean deliveries were elective, patients were included if there was typical time for routine Cesarean section preparation.

Participants by arm

ArmCount
Alexis O C-section Retractor
Alexis O retractor used during C-section
144
Control
Other retractor used during C-section
157
Total301

Withdrawals & dropouts

PeriodReasonFG000FG001
Overall StudyLost to Follow-up89

Baseline characteristics

CharacteristicAlexis O C-section RetractorControlTotal
Age, Categorical
<=18 years
0 Participants0 Participants0 Participants
Age, Categorical
>=65 years
0 Participants0 Participants0 Participants
Age, Categorical
Between 18 and 65 years
144 Participants157 Participants301 Participants
Age, Continuous28.5 years29 years28.8 years
BMI39.9 kg/m240.6 kg/m240.1 kg/m2
Chorioamnionitis8 participants6 participants14 participants
Gravidity3 live births3 live births3 live births
Group beta streptococcus colonization38 participants49 participants87 participants
Low transverse-skin incision130 participants144 participants274 participants
Low transverse-Uterine incision135 participants144 participants279 participants
Region of Enrollment
United States
144 participants157 participants301 participants
Sex: Female, Male
Female
144 Participants157 Participants301 Participants
Sex: Female, Male
Male
0 Participants0 Participants0 Participants
Subcutaneous thickness3.0 cm3.0 cm3.0 cm
Tobacco Use27 participants46 participants73 participants

Adverse events

Event typeEG000
affected / at risk
EG001
affected / at risk
deaths
Total, all-cause mortality
— / —— / —
other
Total, other adverse events
0 / 1440 / 157
serious
Total, serious adverse events
0 / 1440 / 157

Outcome results

Primary

Wound Infection or Disruption

We will compare the number of patients with wound infections or disruptions when the Alexis O C-Section retractor is used vs when it is not used.

Time frame: Time of surgery to 30 days post op

Population: Any SSI or wound disruption during 30 day postoperative period

ArmMeasureValue (NUMBER)
Alexis RetractorWound Infection or Disruption38 participants
ControlWound Infection or Disruption37 participants
Secondary

Secondary Outcomes Will Include the Differences Between the Two Groups.

Secondary outcomes will include the duration of surgery or length of time from skin incision to delivery of the infant, change in hemoglobin, estimated blood loss, and postoperative length of stay, intra-operative or postoperative anti-emetic requirements, need for hospital readmission or emergency room visits, or other complication rates between the two groups.

Time frame: From the time of surgery to 30 days post-op.

Population: infection during 30 day postoperative period

ArmMeasureGroupValue (NUMBER)
Alexis RetractorSecondary Outcomes Will Include the Differences Between the Two Groups.Surgical site infection during 30 day postop20 participants
Alexis RetractorSecondary Outcomes Will Include the Differences Between the Two Groups.Superficial incisional during 30 day postop14 participants
Alexis RetractorSecondary Outcomes Will Include the Differences Between the Two Groups.Deep organ/space during 30 day postop6 participants
Alexis RetractorSecondary Outcomes Will Include the Differences Between the Two Groups.Wound disruption during 30 day postop18 participants
ControlSecondary Outcomes Will Include the Differences Between the Two Groups.Wound disruption during 30 day postop18 participants
ControlSecondary Outcomes Will Include the Differences Between the Two Groups.Surgical site infection during 30 day postop19 participants
ControlSecondary Outcomes Will Include the Differences Between the Two Groups.Deep organ/space during 30 day postop6 participants
ControlSecondary Outcomes Will Include the Differences Between the Two Groups.Superficial incisional during 30 day postop13 participants

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026